Heterogeneity-based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report.

about

Heterogeneity-based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report.

Item

http://www.wikidata.org/entity/Q48091584

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Heterogeneity-based, multiple ...... inib (AZD9291): A case report.

@en

Heterogeneity-based, multiple ...... inib (AZD9291): A case report.

@nl

type

Item

label

Heterogeneity-based, multiple ...... inib (AZD9291): A case report.

@en

Heterogeneity-based, multiple ...... inib (AZD9291): A case report.

@nl

prefLabel

Heterogeneity-based, multiple ...... inib (AZD9291): A case report.

@en

Heterogeneity-based, multiple ...... inib (AZD9291): A case report.

@nl

P1476

Heterogeneity-based, multiple ...... tinib (AZD9291): A case report

@en

P2093

Hongyu Wang

http://www.w3.org/2001/XMLSchema#string

Jianming Ying

http://www.w3.org/2001/XMLSchema#string

Junling Li

http://www.w3.org/2001/XMLSchema#string

Puyuan Xing

http://www.w3.org/2001/XMLSchema#string

Weihua Li

http://www.w3.org/2001/XMLSchema#string

Xiaohong Han

http://www.w3.org/2001/XMLSchema#string

Xingsheng Hu

http://www.w3.org/2001/XMLSchema#string

Xuezhi Hao

http://www.w3.org/2001/XMLSchema#string

Yan Wang

http://www.w3.org/2001/XMLSchema#string

Yutao Liu

http://www.w3.org/2001/XMLSchema#string

P2860

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.

EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.

Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.

Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.

Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors.

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

P304

498-501

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1111/1759-7714.12596

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yuankai Shi

P577

2018-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29411527

http://www.w3.org/2001/XMLSchema#string

P932

5879057

http://www.w3.org/2001/XMLSchema#string